Salix Pharmaceuticals (NASDAQ: SLXP) and TherapeuticsMD (NASDAQ:TXMD) are both specialty & advanced pharmaceuticals companies, but which is the better business? We will compare the two companies based on the strength of their risk, valuation, institutional ownership, earnings, analyst recommendations, dividends and profitability.

Institutional & Insider Ownership

72.5% of TherapeuticsMD shares are owned by institutional investors. 23.9% of TherapeuticsMD shares are owned by company insiders. Strong institutional ownership is an indication that hedge funds, endowments and large money managers believe a stock is poised for long-term growth.

Profitability

This table compares Salix Pharmaceuticals and TherapeuticsMD’s net margins, return on equity and return on assets.

Net Margins Return on Equity Return on Assets
Salix Pharmaceuticals -2,134.34% -305.24% -25.83%
TherapeuticsMD -457.00% -65.16% -58.66%

Analyst Recommendations

This is a summary of current ratings and target prices for Salix Pharmaceuticals and TherapeuticsMD, as provided by MarketBeat.

Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score
Salix Pharmaceuticals 0 0 0 0 N/A
TherapeuticsMD 0 1 10 0 2.91

TherapeuticsMD has a consensus price target of $14.72, suggesting a potential upside of 150.80%. Given TherapeuticsMD’s higher possible upside, analysts plainly believe TherapeuticsMD is more favorable than Salix Pharmaceuticals.

Risk & Volatility

Salix Pharmaceuticals has a beta of 0.94, indicating that its share price is 6% less volatile than the S&P 500. Comparatively, TherapeuticsMD has a beta of 0.92, indicating that its share price is 8% less volatile than the S&P 500.

Earnings and Valuation

This table compares Salix Pharmaceuticals and TherapeuticsMD’s top-line revenue, earnings per share and valuation.

Gross Revenue Price/Sales Ratio NetIncome Earnings Per Share Price/Earnings Ratio
Salix Pharmaceuticals N/A N/A N/A ($6.51) -26.55
TherapeuticsMD $19.36 million 65.62 -$89.87 million ($0.39) -15.05

Salix Pharmaceuticals has higher revenue, but lower earnings than TherapeuticsMD. Salix Pharmaceuticals is trading at a lower price-to-earnings ratio than TherapeuticsMD, indicating that it is currently the more affordable of the two stocks.

Summary

TherapeuticsMD beats Salix Pharmaceuticals on 8 of the 10 factors compared between the two stocks.

About Salix Pharmaceuticals

Salix Pharmaceuticals, Ltd. is a specialty pharmaceutical company engaged in acquiring, developing and commercializing prescription drugs and medical devices used in the treatment of a variety of gastrointestinal disorders. The Company offers over 20 marketed products, such as XIFAXAN550 (rifaximin) tablets, XIFAXAN (rifaximin) tablets, APRISO (mesalamine) extended-release capsules, UCERIS (budesonide MMX) extended release tablets, MOVIPREP, GLUMETZA extended release tablets, RELISTOR subcutaneous injection, UCERIS rectal foam, OSMOPREP tablets, SOLESTA, DEFLUX, FULYZAQ (crofelemer) delayed-release tablets, GIAZO (balsalazide disodium) tablets, CYCLOSET (bromocriptine mesylate) tablets, and FENOGLIDE (fenofibrate) tablets, among others. Its primary product candidates under development include Rifaximin, Methylnaltrexone bromide oral, Ruconest, Rifaximin delayed release or extended intestinal release and Rifaximin soluble solid dispersion (SSD)/next generation.

About TherapeuticsMD

TherapeuticsMD, Inc. is a women’s healthcare company engaged in creating and commercializing products for women. The Company is focused on pursuing regulatory approvals and pre-commercialization activities necessary for commercialization of its hormone therapy pharmaceutical products. Its drug candidates used in clinical trials are designed to alleviate symptoms of and reduce health risks resulting from menopause-related hormone deficiencies, including hot flashes, osteoporosis and vaginal discomfort. With its SYMBODA technology, it is developing hormone therapy pharmaceutical products to enable delivery of bio-identical hormones through dosage forms and administration routes. Its product line includes vitaTrue, vitaPearl, vitaMedMD Plus, vitaMedMD One Prenatal Multivitamin, vitaMedMD Plus Rx Prenatal Multivitamin, vitaMedMD One Rx Prenatal Multivitamin, vitaMedMD Iron 21/7, vitaMedMD Vitamin D3 50,000 IU, BocaGreenMD Prena1 Pearl and BocaGreenMD Prena1 Chew.

Receive News & Ratings for Salix Pharmaceuticals Ltd. Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Salix Pharmaceuticals Ltd. and related companies with MarketBeat.com's FREE daily email newsletter.